The takeaway
Iradimed Co shows a pronounced seasonal pattern over 10 years of data — strongest in November (+8.2%) and softest in February (−2.9%).
Right now
In July, the stock has risen 60% of years, averaging +5.8%, about +3.7 pts better than the S&P 500.
The full picture
Iradimed Co's most dependable month has been November, higher in 9 of 10 years; February has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in November (+5.9 pts); it has trailed the market most in February (−2.7 pts).
“vs S&P” is Iradimed Co’s average for a month minus the S&P 500’s average for that same month — isolating Iradimed Co’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, November has closed higher 100% of the time versus 90% across the last 10 years — the pattern is holding.
Figures are the typical (median) November return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
This is a stock you can almost set a calendar by, and November is the anchor — it has closed higher in 9 of 10 Novembers, the steadiest beat on its year.
The strength looks broad-based rather than freakish: its average (+8.2%) and median (+9.7%) sit close together, so no single blow-out year is flattering the figure. Few months are steadier: November's returns vary by just 6.8% year to year. Better still, that strength is the stock's own and not just a buoyant market — November has outpaced the S&P 500 by +5.9 points on average. Few peers keep such company in November — the typical stock clears it just 62% of the time.
It doesn't stand entirely alone — March, May, and June have leaned firm as well, if less emphatically. On the other side of the ledger, February has been the soft spot — the weakest of 3 months that average a loss (−2.9%), and the edge isn't year-round — the stock has trailed the S&P 500 in February, April, and October. Its roughest month on record was a −44.4% October in 2016 — a reminder of how hard even a seasonal name can fall.
November has now closed higher 6 years running. Reassuringly, the tendency has held its shape: the recent five years still track the years behind them.
For a stock this dependable in November, the sharper question is the rest of the year — outside its strong stretch, the calendar gives far less to lean on.
Short answers on the stock's best month (November), its worst (February), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2016 its best month (November, +8.2%) has run well ahead of its worst (February, −2.9%) — the heatmap above shows how steady that gap has been year to year.
November has been the strongest, averaging +8.2% and closing higher in 9 of 10 years since 2016.
It's the weakest, averaging −2.9% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade